

December 19, 2006

Ono Pharmaceutical Co., Ltd.

Public Relations

Phone: 06-6263-5670

Fax: 06-6263-2950

**Announcement of the Launch of Elaspol[®] 100 for Injection for
Acute Lung Injury Associated with SIRS in Korea**

Ono Pharmaceutical Co., Ltd. (Osaka, Japan) announced today that Dong-A Pharmaceutical Co., Ltd. (Seoul, Korea) will launch Elaspol[®] 100 for Injection on December 20, 2006 in Korea based on the License Agreement* signed with Ono in November 2003. Ono will manufacture its finished product (vial product) and supply it to Dong-A.

Elaspol[®] 100 for Injection is the world's first neutrophil elastase inhibitor discovered by Ono. In Japan, it was approved in April 2002 for the indication of acute lung injury associated with systemic inflammatory response syndrome (SIRS) and was launched in June 2002.

SIRS is a systemic inflammatory reaction caused by infection, surgical invasion, burn, trauma, pancreatitis, etc. When such a condition persists, it may cause failures not only in the lungs but also in the liver, kidneys and other organs leading to the multiple organ failure in some cases.

It is believed that neutrophil elastase, which is an enzyme released from neutrophil (a type of white blood cell) accumulating locally in the lungs, is deeply involved in acute lung injury particularly occurring earlier than other organ failures associated with SIRS, and that the enzyme damages lung tissue, leading to rapid deterioration of respiratory function and further leading to death in some cases.

By selectively inhibiting neutrophil elastase and improving the respiratory function, Elaspol 100 for Injection can permit patients' early weaning from mechanical ventilation and early discharge from the ICU (intensive care unit).

* License Agreement signed in November 2003

Exclusive license that Dong-A develops and markets Elaspol[®] 100 for Injection in Korea